

Press release

MEDICA S.P.A.

**INVESTMENT OF 32% IN THE SHARE CAPITAL OF THE NEWLY
ESTABLISHED COMPANY MEDICO MEDTECH CO LTD**

Medolla (MO), 15 July 2024 – Medica S.p.A., an integrated Italian biomedical and MedTech group with a strong international footprint, announces that it has increased the investment in the share capital of the newly established company Medico MedTech Co. Ltd, trading company based in Suzhou - China, whose majority shareholder is Suzhou Huisheng Medical Science & Technology Co. Ltd, reaching the percentage of 32% for a total consideration of 11.2 million RMB.

The increase in the participation fee is consequent to the occurrence of a series of conditions present in the previous agreement, which allow Medica SpA to increase the share from 20% to 32% of the share capital of Medico MedTech Co. Ltd.

Medica Profile

Medica Group is operating since 1985 in the biomedical district of Mirandola (Italy). Development of innovative products for blood purification has always been company's core business. Thanks to the activity of two extremely dynamic R&D groups (medical equipment, membranes and disposable), the Group competes successfully in several markets, namely:

- **Medical** (dialysis, CRRT, ECCO2, Apheresis, DFPP, CHF, HIPEC, pre-transplant organ perfusion, bioregenerative medicine, gastroenterology, urodynamics, oxygen humidification).
- **Microbiological purification of water**
- **Industrial automation** for the biomedical sector.

R&D focus has been integrated over the years with a highly automated production systems in several facilities, and with different commercial entities, both in Italy and abroad.

The key success factors of the Group are:

- **extrusion of hollow fiber membranes** for hemofiltration, plasmapheresis, cascade filtration, oxygen humidification, ultrafiltration and microfiltration of water
- **vertical integration**, proved by the ability to manage not only the design and development of medical disposables and equipment, and the development of the automation technologies required for their production as well.
- **International recognition with significant share of export**, with sales in over 60 countries.

The Medica group closed its consolidated financial statements for 2023 with revenues of 80.0 million euros (50.9 million euros in 2022), EBITDA of 11.7 million euros (11.2 million euros in 2022), EBIT of € 4.6 million (€ 5.3 million in 2022) and net profit of € 2.5 million (€ 4.0 million in 2022).

For information:

Investor Relations Medica

Giovanni Plasmati

(+39) 0535 51159

giovanni.plasmati@medica-spa.com

Euronext Growth Advisor

CFO SIM S.p.A.

(+39) 02 303431

ecm@cfosim.com